JP2017521060A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017521060A5 JP2017521060A5 JP2016573923A JP2016573923A JP2017521060A5 JP 2017521060 A5 JP2017521060 A5 JP 2017521060A5 JP 2016573923 A JP2016573923 A JP 2016573923A JP 2016573923 A JP2016573923 A JP 2016573923A JP 2017521060 A5 JP2017521060 A5 JP 2017521060A5
- Authority
- JP
- Japan
- Prior art keywords
- rodent
- human
- endogenous
- pdcd1
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000283984 Rodentia Species 0.000 claims description 158
- 229920001184 polypeptide Polymers 0.000 claims description 65
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 65
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 65
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 claims description 53
- 238000000034 method Methods 0.000 claims description 52
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims description 34
- 102000048362 human PDCD1 Human genes 0.000 claims description 34
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 23
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 23
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 19
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 210000004027 cell Anatomy 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 13
- 239000012634 fragment Substances 0.000 claims description 10
- 230000008685 targeting Effects 0.000 claims description 9
- 108700024394 Exon Proteins 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 230000003834 intracellular effect Effects 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 210000004881 tumor cell Anatomy 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000004614 tumor growth Effects 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims description 2
- 210000001161 mammalian embryo Anatomy 0.000 claims description 2
- 230000034994 death Effects 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 239000000203 mixture Substances 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 229940122544 PD-1 agonist Drugs 0.000 description 1
- 229940124060 PD-1 antagonist Drugs 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021049567A JP7612475B2 (ja) | 2014-06-19 | 2021-03-24 | ヒト化プログラム細胞死１遺伝子を持つ非ヒト動物 |
| JP2023069178A JP7720349B2 (ja) | 2014-06-19 | 2023-04-20 | ヒト化プログラム細胞死１遺伝子を持つ非ヒト動物 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462014181P | 2014-06-19 | 2014-06-19 | |
| US62/014,181 | 2014-06-19 | ||
| US201462086518P | 2014-12-02 | 2014-12-02 | |
| US62/086,518 | 2014-12-02 | ||
| US201562138221P | 2015-03-25 | 2015-03-25 | |
| US62/138,221 | 2015-03-25 | ||
| PCT/US2015/036649 WO2015196051A1 (en) | 2014-06-19 | 2015-06-19 | Non-human animals having a humanized programmed cell death 1 gene |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021049567A Division JP7612475B2 (ja) | 2014-06-19 | 2021-03-24 | ヒト化プログラム細胞死１遺伝子を持つ非ヒト動物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017521060A JP2017521060A (ja) | 2017-08-03 |
| JP2017521060A5 true JP2017521060A5 (cg-RX-API-DMAC7.html) | 2018-08-02 |
| JP6904707B2 JP6904707B2 (ja) | 2021-07-21 |
Family
ID=53546709
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016573923A Active JP6904707B2 (ja) | 2014-06-19 | 2015-06-19 | ヒト化プログラム細胞死１遺伝子を持つ非ヒト動物 |
| JP2021049567A Active JP7612475B2 (ja) | 2014-06-19 | 2021-03-24 | ヒト化プログラム細胞死１遺伝子を持つ非ヒト動物 |
| JP2023069178A Active JP7720349B2 (ja) | 2014-06-19 | 2023-04-20 | ヒト化プログラム細胞死１遺伝子を持つ非ヒト動物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021049567A Active JP7612475B2 (ja) | 2014-06-19 | 2021-03-24 | ヒト化プログラム細胞死１遺伝子を持つ非ヒト動物 |
| JP2023069178A Active JP7720349B2 (ja) | 2014-06-19 | 2023-04-20 | ヒト化プログラム細胞死１遺伝子を持つ非ヒト動物 |
Country Status (24)
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8307177B2 (en) | 2008-09-05 | 2012-11-06 | Commvault Systems, Inc. | Systems and methods for management of virtualization data |
| TW202442680A (zh) | 2008-12-09 | 2024-11-01 | 美商建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
| US9461881B2 (en) | 2011-09-30 | 2016-10-04 | Commvault Systems, Inc. | Migration of existing computing systems to cloud computing sites or virtual machines |
| US20140181038A1 (en) | 2012-12-21 | 2014-06-26 | Commvault Systems, Inc. | Systems and methods to categorize unprotected virtual machines |
| US9378035B2 (en) | 2012-12-28 | 2016-06-28 | Commvault Systems, Inc. | Systems and methods for repurposing virtual machines |
| ES2845609T3 (es) | 2013-05-02 | 2021-07-27 | Anaptysbio Inc | Anticuerpos dirigidos contra muerte programada-1 (PD-1) |
| BR112016029650A2 (pt) * | 2014-06-19 | 2017-10-24 | Regeneron Pharma | roedor, polipeptídeo pd-1, célula isolada ou tecido de roedor, célula-tronco embrionária de roedor, métodos de produzir um roedor, de reduzir o crescimento de tumor em um roedor, de matar células tumorais em um roedor e de avaliar as propriedades farmacocinéticas de uma droga que direciona pd-1 humano, e, modelo de tumor de roedor? |
| PL3689140T3 (pl) | 2014-11-24 | 2022-09-05 | Regeneron Pharmaceuticals, Inc. | Zwierzęta inne niż ludzie eksprymujące humanizowany kompleks CD3 |
| IL286403B2 (en) | 2014-12-05 | 2023-10-01 | Regeneron Pharma | Non-human animals possess a humanized CLUSTER OF DIFFERENTIATION 47 gene |
| HUE067123T2 (hu) | 2014-12-09 | 2024-10-28 | Regeneron Pharma | Humanizált differenciációs klaszter 274 génnel rendelkezõ nem humán állatok |
| US9563514B2 (en) | 2015-06-19 | 2017-02-07 | Commvault Systems, Inc. | Assignment of proxies for virtual-machine secondary copy operations including streaming backup jobs |
| US10084873B2 (en) | 2015-06-19 | 2018-09-25 | Commvault Systems, Inc. | Assignment of data agent proxies for executing virtual-machine secondary copy operations including streaming backup jobs |
| WO2017011580A2 (en) | 2015-07-13 | 2017-01-19 | Cytomx Therapeutics, Inc. | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
| JP6997708B2 (ja) | 2015-11-20 | 2022-02-04 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化されたｌｙｍｐｈｏｃｙｔｅ－ａｃｔｉｖａｔｉｏｎ ｇｅｎｅ ３遺伝子を有する非ヒト動物 |
| SG11201806176PA (en) * | 2016-02-04 | 2018-08-30 | Regeneron Pharma | Non-human animals having an engineered angptl8 gene |
| AU2017228293B2 (en) | 2016-02-29 | 2023-05-25 | Regeneron Pharmaceuticals, Inc. | Rodents having a humanized Tmprss gene |
| TWI755395B (zh) | 2016-05-13 | 2022-02-21 | 美商再生元醫藥公司 | 抗-pd-1抗體與輻射治療癌症之組合 |
| US11352413B2 (en) | 2016-05-17 | 2022-06-07 | Albert Einstein College Of Medicine | Engineered PD-1 variants |
| RS66700B1 (sr) * | 2016-06-03 | 2025-05-30 | Regeneron Pharma | Glodari koji eksprimiraju egzogenu terminalnu dezoksinukleotidil transferazu |
| US10912287B2 (en) | 2016-06-28 | 2021-02-09 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd | Genetically modified mice expressing humanized PD-1 |
| CN107815466B (zh) | 2016-08-31 | 2020-03-13 | 百奥赛图江苏基因生物技术有限公司 | 人源化基因改造动物模型的制备方法及应用 |
| WO2018041118A1 (en) * | 2016-08-31 | 2018-03-08 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric pd-l1 |
| EP3534950A4 (en) | 2016-11-01 | 2020-05-06 | AnaptysBio, Inc. | Antibodies directed against programmed death- 1 (pd-1) |
| CN107828722B (zh) * | 2016-11-04 | 2021-07-23 | 北京泰盛生物科技有限公司 | 特异性表达pd-1的干细胞、其鉴定和分离方法及用途 |
| US10736976B2 (en) * | 2016-12-01 | 2020-08-11 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging |
| MX2019008207A (es) | 2017-01-09 | 2019-12-11 | Tesaro Inc | Métodos para tratar el cáncer con anticuerpos anti-pd-1. |
| IL268479B2 (en) | 2017-02-21 | 2024-06-01 | Regeneron Pharma | Anti-PD-1 antibodies for the treatment of lung cancer |
| US10949308B2 (en) | 2017-03-15 | 2021-03-16 | Commvault Systems, Inc. | Application aware backup of virtual machines |
| US10853195B2 (en) | 2017-03-31 | 2020-12-01 | Commvault Systems, Inc. | Granular restoration of virtual machine application data |
| CN109136274B (zh) * | 2017-06-19 | 2021-04-23 | 百奥赛图江苏基因生物技术有限公司 | 人源化cd40基因改造动物模型的制备方法及应用 |
| CN109136275B (zh) * | 2017-06-19 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化gitr基因改造动物模型的制备方法及应用 |
| CN109136261B (zh) * | 2017-06-19 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化cd28基因改造动物模型的制备方法及应用 |
| CN109280674B (zh) * | 2017-07-21 | 2020-12-01 | 北京百奥赛图基因生物技术有限公司 | 一种筛选抗体的非人模式动物的构建方法及其应用 |
| EP4276185A3 (en) * | 2017-09-29 | 2024-02-21 | Regeneron Pharmaceuticals, Inc. | Rodents comprising a humanized ttr locus and methods of use |
| WO2019072241A1 (en) | 2017-10-13 | 2019-04-18 | Beijing Biocytogen Co., Ltd | NON-HUMAN ANIMAL GENETICALLY MODIFIED WITH PD-1 HUMAN OR CHIMERIC |
| CN109666701B (zh) * | 2017-10-13 | 2021-08-24 | 百奥赛图(北京)医药科技股份有限公司 | 一种pd-1基因修饰人源化动物模型的构建方法及其应用 |
| IL274740B2 (en) | 2017-11-30 | 2024-06-01 | Regeneron Pharma | Non-human animals comprising a humanized trkb locus |
| CA3093850A1 (en) | 2018-03-26 | 2019-10-03 | Regeneron Pharmaceuticals, Inc. | Humanized rodents for testing therapeutic agents |
| FI3823443T3 (fi) | 2018-07-16 | 2024-07-25 | Regeneron Pharma | Ditra-taudin jyrsijämallit ja niiden käyttö |
| CN109266656B (zh) * | 2018-10-10 | 2021-02-19 | 江苏集萃药康生物科技股份有限公司 | 一种PD1人源化BALB/c小鼠模型的构建方法及其应用 |
| CN109452229B (zh) * | 2018-11-19 | 2021-10-22 | 百奥赛图(北京)医药科技股份有限公司 | 狗源化pd-1基因改造动物模型的制备方法及应用 |
| WO2021018198A1 (en) * | 2019-07-29 | 2021-02-04 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric il33 |
| CN115175559A (zh) * | 2020-01-28 | 2022-10-11 | 瑞泽恩制药公司 | 包含人源化pnpla3基因座的非人动物及其使用方法 |
| US11656951B2 (en) | 2020-10-28 | 2023-05-23 | Commvault Systems, Inc. | Data loss vulnerability detection |
| JPWO2023176881A1 (cg-RX-API-DMAC7.html) | 2022-03-16 | 2023-09-21 | ||
| CN119451570A (zh) * | 2022-06-29 | 2025-02-14 | 百奥赛图(北京)医药科技股份有限公司 | 一种osm、osmr、il31ra和/或il31基因修饰的非人动物 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2143491C (en) | 1994-03-01 | 2011-02-22 | Yasumasa Ishida | A novel peptide related to human programmed cell death and dna encoding it |
| US5670356A (en) | 1994-12-12 | 1997-09-23 | Promega Corporation | Modified luciferase |
| US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
| WO2002000730A2 (en) | 2000-06-28 | 2002-01-03 | Genetics Institute, Llc. | Pd-l2 molecules: novel pd-1 ligands and uses therefor |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7414171B2 (en) | 2000-11-15 | 2008-08-19 | Ono Pharmaceutical Co., Ltd. | PD-1-lacking mouse and use thereof |
| US20040033497A1 (en) * | 2002-08-13 | 2004-02-19 | Alarcon-Riquelme Marta E. | Polymorphisms of PD-1 |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| ES2587344T3 (es) * | 2003-12-24 | 2016-10-24 | Novo Nordisk A/S | Ratón transgénico que comprende un polinucleótido que codifica C5aR humano o humanizado |
| WO2005060739A1 (en) | 2003-12-24 | 2005-07-07 | G2 Inflammation Pty Ltd | Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar |
| EP1802193B1 (en) | 2004-10-19 | 2014-04-30 | Regeneron Pharmaceuticals, Inc. | Method for generating a mouse homozygous for a genetic modification |
| EP1896582A4 (en) * | 2005-05-09 | 2009-04-08 | Ono Pharmaceutical Co | HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS |
| US20070054360A1 (en) * | 2005-05-12 | 2007-03-08 | Zeren Gao | Compositions and methods for modulating immune responses |
| MX349137B (es) * | 2005-06-08 | 2017-07-13 | Dana-Farber Cancer Inst | Metodos y composiciones para el tratamiento de infecciones persistentes y cancer por inhibicion de la ruta de muerte celular programada (pd-1). |
| TW202442680A (zh) | 2008-12-09 | 2024-11-01 | 美商建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
| RU2425880C2 (ru) | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
| US8354389B2 (en) | 2009-08-14 | 2013-01-15 | Regeneron Pharmaceuticals, Inc. | miRNA-regulated differentiation-dependent self-deleting cassette |
| TW201134488A (en) * | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| US8871996B2 (en) * | 2010-06-09 | 2014-10-28 | Regeneron Pharmaceuticals, Inc. | Mice expressing human voltage-gated sodium channels |
| CA2853731C (en) | 2011-10-28 | 2021-05-18 | Regeneron Pharmaceuticals, Inc. | Humanized il-6 and il-6 receptor |
| ES2858978T3 (es) * | 2011-10-28 | 2021-09-30 | Regeneron Pharma | Ratones con receptores de linfocitos T genéticamente modificados |
| ES2741649T3 (es) | 2011-10-28 | 2020-02-11 | Regeneron Pharma | Ratones con complejo mayor de histocompatibilidad modificado genéticamente |
| CN104039133B (zh) | 2011-10-28 | 2018-05-04 | 瑞泽恩制药公司 | 表达嵌合主要组织相容性复合物(mhc)ii类分子的基因修饰小鼠 |
| IL299887B2 (en) | 2012-11-05 | 2024-09-01 | Regeneron Pharma | Genetically modified non-human animals and methods of use thereof |
| KR102714111B1 (ko) | 2013-02-20 | 2024-10-11 | 리제너론 파아마슈티컬스, 인크. | 사람화된 ｔ-세포 보조-수용체를 발현하는 마우스 |
| HRP20181866T1 (hr) | 2013-02-22 | 2019-01-25 | Regeneron Pharmaceuticals, Inc. | Miševi koji izražavaju humanizirane komplekse glavne histokompatibilnosti |
| KR102370419B1 (ko) | 2013-09-23 | 2022-03-04 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화된 신호-조절 단백질 유전자를 가지는 비-인간 동물 |
| WO2015077071A1 (en) | 2013-11-19 | 2015-05-28 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized b-cell activating factor gene |
| DK3129400T3 (da) | 2014-04-08 | 2020-06-08 | Regeneron Pharma | Ikke-humane dyr med humaniserede Fc-gamma-receptorer |
| NO2785538T3 (cg-RX-API-DMAC7.html) | 2014-05-07 | 2018-08-04 | ||
| PT3482629T (pt) | 2014-05-19 | 2021-02-18 | Univ Yale | Animais não humanos geneticamente modificados que expressam epo humana |
| BR112016029650A2 (pt) | 2014-06-19 | 2017-10-24 | Regeneron Pharma | roedor, polipeptídeo pd-1, célula isolada ou tecido de roedor, célula-tronco embrionária de roedor, métodos de produzir um roedor, de reduzir o crescimento de tumor em um roedor, de matar células tumorais em um roedor e de avaliar as propriedades farmacocinéticas de uma droga que direciona pd-1 humano, e, modelo de tumor de roedor? |
-
2015
- 2015-06-19 BR BR112016029650A patent/BR112016029650A2/pt not_active IP Right Cessation
- 2015-06-19 JP JP2016573923A patent/JP6904707B2/ja active Active
- 2015-06-19 HR HRP20200613TT patent/HRP20200613T1/hr unknown
- 2015-06-19 AU AU2015276978A patent/AU2015276978B2/en active Active
- 2015-06-19 SG SG10201811116UA patent/SG10201811116UA/en unknown
- 2015-06-19 WO PCT/US2015/036649 patent/WO2015196051A1/en not_active Ceased
- 2015-06-19 KR KR1020167035520A patent/KR102482295B1/ko active Active
- 2015-06-19 ES ES15738177T patent/ES2783424T3/es active Active
- 2015-06-19 CN CN201580033075.2A patent/CN106604635B/zh active Active
- 2015-06-19 IL IL287519A patent/IL287519B2/en unknown
- 2015-06-19 HU HUE15738177A patent/HUE048677T2/hu unknown
- 2015-06-19 RS RS20200389A patent/RS60097B1/sr unknown
- 2015-06-19 CN CN201911291579.0A patent/CN110923256B/zh active Active
- 2015-06-19 US US14/744,592 patent/US10390522B2/en active Active
- 2015-06-19 SG SG11201609638RA patent/SG11201609638RA/en unknown
- 2015-06-19 DK DK15738177.3T patent/DK3157956T3/da active
- 2015-06-19 PT PT157381773T patent/PT3157956T/pt unknown
- 2015-06-19 SI SI201531158T patent/SI3157956T1/sl unknown
- 2015-06-19 SM SM20200184T patent/SMT202000184T1/it unknown
- 2015-06-19 PL PL15738177T patent/PL3157956T3/pl unknown
- 2015-06-19 CA CA2951278A patent/CA2951278A1/en active Pending
- 2015-06-19 RU RU2016149434A patent/RU2735958C2/ru active
- 2015-06-19 EP EP15738177.3A patent/EP3157956B1/en active Active
- 2015-06-19 EP EP19215361.7A patent/EP3683238A1/en active Pending
- 2015-06-19 KR KR1020227045421A patent/KR102594863B1/ko active Active
- 2015-06-19 MX MX2016016903A patent/MX2016016903A/es unknown
- 2015-06-19 LT LTEP15738177.3T patent/LT3157956T/lt unknown
-
2016
- 2016-11-23 IL IL249145A patent/IL249145B/en unknown
-
2018
- 2018-03-20 US US15/926,586 patent/US20180206462A1/en not_active Abandoned
-
2019
- 2019-11-04 US US16/673,119 patent/US11684050B2/en active Active
-
2020
- 2020-04-22 CY CY20201100369T patent/CY1122940T1/el unknown
-
2021
- 2021-03-24 JP JP2021049567A patent/JP7612475B2/ja active Active
- 2021-05-14 AU AU2021203100A patent/AU2021203100B2/en active Active
-
2023
- 2023-04-20 JP JP2023069178A patent/JP7720349B2/ja active Active
- 2023-05-12 US US18/316,461 patent/US20240298619A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017521060A5 (cg-RX-API-DMAC7.html) | ||
| RU2016149434A (ru) | Животные, отличные от человека, имеющие гуманизированный ген 1 запрограммированный гибели клеток | |
| US11178860B2 (en) | Humanized C5 animals | |
| US11317611B2 (en) | Genetically modified non-human animal with human or chimeric PD-L1 | |
| JP2018500896A5 (cg-RX-API-DMAC7.html) | ||
| US11234420B2 (en) | Method for constructing PD-1 gene modified humanized animal model and use thereof | |
| HRP20231121T1 (hr) | Životinje koje nisu ljudi, koje imaju gen za humanizirani protein koji regulira signale | |
| JP2021094035A5 (cg-RX-API-DMAC7.html) | ||
| JP2018533963A5 (cg-RX-API-DMAC7.html) | ||
| RU2018117944A (ru) | Животные, отличные от человека, имеющие гуманизированный ген активации лимфоцитов-3 | |
| JP2019505216A5 (cg-RX-API-DMAC7.html) | ||
| AU2018225745A1 (en) | Humanized model of kidney and liver disorders | |
| RU2018130003A (ru) | Животные, отличные от человека, имеющие сконструированный ген angptl8 | |
| CN109136275A (zh) | 人源化gitr基因改造动物模型的制备方法及应用 | |
| JP7504030B2 (ja) | 進行性骨化性線維異形成症のげっ歯類モデル | |
| JP7765403B2 (ja) | ヒト化ｃｘｃｌ１３遺伝子を有する非ヒト動物 | |
| CN119331910A (zh) | 一种gdf8基因修饰的非人动物 | |
| US20230413791A1 (en) | Non-human animals having a humanized clec9a gene | |
| US20220192165A1 (en) | Non-human animals having a humanized tslp gene, a humanized tslp receptor gene, and/or a humanized il7ra gene | |
| Dey et al. | Differential temporal changes in brain and gut substance P mRNA expression throughout the time-course of cisplatin-induced vomiting in the least shrew (Cryptotis parva) | |
| RU2795136C2 (ru) | Модель прогрессирующей оссифицирующей фибродисплазии на грызунах | |
| JP6666001B2 (ja) | 金属高感度・高感受性の金属アレルギー動物モデルの樹立 | |
| JPWO2007004337A1 (ja) | 白髪発症モデル動物、白髪発症モデル動物の樹立方法、白髪発症モデル動物の継代方法、白髪発症の研究方法、白髪発症制御手段のスクリーニング方法、白髪発症制御用組成物 | |
| CN120174021A (zh) | 一种tau基因修饰的非人动物 | |
| JP2014073080A (ja) | 神経芽腫モデルマウス |